Cargando…

Variant of Concern-Matched COVID-19 Convalescent Plasma Usage in Seronegative Hospitalized Patients

COVID-19 convalescent plasma (CCP) has been the only specific anti-viral therapy against SARS-CoV-2 available for more than one year. Following the negative results from most randomized controlled trials on its efficacy in COVID-19 hospitalized patients and the availability of anti-spike monoclonal...

Descripción completa

Detalles Bibliográficos
Autores principales:	Franchini, Massimo, Focosi, Daniele, Percivalle, Elena, Beccaria, Massimiliano, Garuti, Martina, Arar, Omar, Pecoriello, Antonietta, Spreafico, Fabio, Greco, Graziana, Bertacco, Stefano, Ghirardini, Marco, Santini, Tiziana, Schiavulli, Michele, Stefania, Muzzica, Gagliardo, Thaililja, Sammartino, Josè Camilla, Ferrari, Alessandro, Zani, Matteo, Ballotari, Alessia, Glingani, Claudia, Baldanti, Fausto
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9323140/ https://www.ncbi.nlm.nih.gov/pubmed/35891421 http://dx.doi.org/10.3390/v14071443

Ejemplares similares

Impact of pathogen reduction technology on neutralizing antibody titer in COVID-19 convalescent plasma
por: Franchini, Massimo, et al.
Publicado: (2022)

Correlation between ABO blood group and neutralizing anti-SARS-CoV-2 antibody titers in convalescent plasma donations
por: Franchini, M., et al.
Publicado: (2022)

Convalescent Plasma for Hospitalized COVID-19 Patients: A Single-Center Experience
por: Franchini, Massimo, et al.
Publicado: (2022)

Hemophagocytic Lymphohistiocytosis in a Patient With Acute Respiratory Distress Syndrome Secondary to SARS-CoV-2 Infection
por: Greco, Graziana Francesca, et al.
Publicado: (2020)

Convalescent plasma for coronavirus disease 2019 in pregnancy: a case report and review
por: Grisolia, Gianpaolo, et al.
Publicado: (2020)

Higher testosterone is associated with increased inflammatory markers in women with SARS-CoV-2 pneumonia: preliminary results from an observational study
por: Di Stasi, V., et al.
Publicado: (2021)

The Three Pillars of COVID-19 Convalescent Plasma Therapy
por: Franchini, Massimo, et al.
Publicado: (2021)

Biomarkers of Endothelial Damage in Distinct Phases of Multisystem Inflammatory Syndrome in Children
por: Gelzo, Monica, et al.
Publicado: (2022)

Dynamics of anti-SARS-CoV-2 antibodies in repeat convalescent plasma donors
por: Franchini, Massimo, et al.
Publicado: (2021)

Safety and Efficacy of Convalescent Plasma in Elderly COVID-19 Patients: The RESCUE Trial
por: Franchini, Massimo, et al.
Publicado: (2021)

Impact of pathogen-reduction technologies on COVID-19 convalescent plasma potency
por: Focosi, D., et al.
Publicado: (2021)

Home and Out-of-Hospital Therapy with COVID-19 Convalescent Plasma in Europe
por: Focosi, Daniele, et al.
Publicado: (2022)

Early and persistent viral clearance in COVID-19 patients treated with convalescent plasma
por: Franchini, Massimo, et al.
Publicado: (2021)

Safety and Efficacy of Convalescent Plasma in COVID-19: An Overview of Systematic Reviews
por: Franchini, Massimo, et al.
Publicado: (2021)

COVID-19 Convalescent Plasma for the Treatment of Immunocompromised Patients: A Systematic Review and Meta-analysis
por: Senefeld, Jonathon W., et al.
Publicado: (2023)

Convalescent plasma for COVID-19. TSUNAMI is not the final word
por: Franchini, Massimo, et al.
Publicado: (2022)

Convalescent Plasma for Pregnant Women with COVID-19: A Systematic Literature Review
por: Franchini, Massimo, et al.
Publicado: (2021)

Mortality reduction in 46 patients with severe COVID-19 treated with hyperimmune plasma. A proof-of-concept, single-arm, multicenter trial
por: Perotti, Cesare, et al.
Publicado: (2020)

On the Need to Determine the Contribution of Anti-Nucleocapsid Antibodies as Potential Contributors to COVID-19 Convalescent Plasma Efficacy
por: Focosi, Daniele, et al.
Publicado: (2022)

WHO Is Recommending against the Use of COVID-19 Convalescent Plasma in Immunocompromised Patients?
por: Franchini, Massimo, et al.
Publicado: (2023)

Convalescent plasma in outpatients with COVID-19
por: Focosi, Daniele, et al.
Publicado: (2022)

Analysis of anti-Omicron neutralizing antibody titers in different vaccinated and unvaccinated convalescent plasma sources
por: Sullivan, David J, et al.
Publicado: (2022)

COVID-19 Convalescent Plasma and Clinical Trials: Understanding Conflicting Outcomes
por: Focosi, Daniele, et al.
Publicado: (2022)

High-Dose Convalescent Plasma for Treatment of Severe COVID-19
por: Focosi, Daniele, et al.
Publicado: (2022)

Analysis of anti-SARS-CoV-2 Omicron-neutralizing antibody titers in different vaccinated and unvaccinated convalescent plasma sources
por: Sullivan, David J., et al.
Publicado: (2022)

The art of the possible in approaching efficacy trials for COVID19 convalescent plasma
por: Focosi, Daniele, et al.
Publicado: (2021)

Convalescent plasma for COVID-19 in oncohematological patients: a call for revision of the European Conference on Infections in Leukemia-9 (ECIL-9) guidelines
por: Focosi, Daniele, et al.
Publicado: (2023)

Is a single COVID-19 vaccine dose enough in convalescents ?
por: Focosi, Daniele, et al.
Publicado: (2021)

Patient-blood management for COVID19 convalescent plasma therapy: relevance of affinity and donor–recipient differences in concentration of neutralizing antibodies
por: Focosi, Daniele, et al.
Publicado: (2021)

Efficacy and Safety of COVID-19 Convalescent Plasma in Hospitalized Patients—An Open-Label Phase II Clinical Trial
por: Grubovic Rastvorceva, Rada M., et al.
Publicado: (2022)

Convalescent Plasma Therapy for COVID-19: State of the Art
por: Focosi, Daniele, et al.
Publicado: (2020)

What is the optimal usage of coronavirus disease 2019 convalescent plasma donations?
por: Focosi, Daniele, et al.
Publicado: (2021)

COVID-19 Convalescent Plasma Is More than Neutralizing Antibodies: A Narrative Review of Potential Beneficial and Detrimental Co-Factors
por: Focosi, Daniele, et al.
Publicado: (2021)

Low testosterone levels predict clinical adverse outcomes in sars-cov-2 pneumonia patients
por: Rastrelli, Giulia, et al.
Publicado: (2022)

Real-life lack of evidence of viable SARS-CoV-2 transmission via inanimate surfaces: The SURFACE study
por: Sammartino, José Camilla, et al.
Publicado: (2023)

SARS-CoV-2 S1 Subunit Booster Vaccination Elicits Robust Humoral Immune Responses in Aged Mice
por: Kim, Eun, et al.
Publicado: (2023)

Evaluation of the Neutralizing Antibodies Response against 14 SARS-CoV-2 Variants in BNT162b2 Vaccinated Naïve and COVID-19 Positive Healthcare Workers from a Northern Italian Hospital
por: Sammartino, Josè Camilla, et al.
Publicado: (2022)

Low testosterone levels predict clinical adverse outcomes in sars-cov-2 pneumonia patients
por: Rastrelli, Prof. Giulia, et al.
Publicado: (2022)

How Safe Is COVID-19 Convalescent Plasma?
por: Franchini, Massimo, et al.
Publicado: (2021)

SARS-CoV-2 specific T-cell immunity in COVID-19 convalescent patients and unexposed controls measured by ex vivo ELISpot assay
por: Cassaniti, Irene, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_qp3e4dnd1t46eit7c39btcqj8b